ReviewClinical hypertension2020
Uric acid and cardiometabolic diseases.
Review in Clinical hypertension, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Epidemiology of metabolic dysfunction-associated steatotic liver disease/metabolic dysfunction-associated steatohepatitis and associated cardiometabolic factors in adults in China (2013-2023): A systematic review and meta-analysis.World journal of gastroenterology · 2025Pooled it
- Risk Factors Related to the Development of Nonalcoholic Fatty Liver: A Systematic Review.Canadian journal of gastroenterology & hepatology · 2025Pooled it
- A protection motivation theory-guided telehealth coaching program for middle-aged adults with cardiometabolic risk: A feasibility trial.BMC public health · 2025Trial
- Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial.Lipids in health and disease · 2024Trial
- Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease.Scientific reports · 2023Trial
- Coping Strategies Influence Cardiometabolic Risk Factors in Chronic Psychological Stress: A Post Hoc Analysis of A Randomized Pilot Study.Nutrients · 2021Trial
- ABCG2 transporter: Structural and functional associations with gout (Review).International journal of molecular medicine · 2026Review
- Metabolic and hormonal correlates of leptin, uric acid and soluble neprilysin in polycystic ovary syndrome/ Polyendocrine Metabolic Ovarian Syndrome.BMC endocrine disorders · 2026Article
- Article
- A risk assessment nomogram for cardiac remodeling in the multimorbid geriatric patients: a retrospective study.BMC geriatrics · 2026Article
- Serum Uric Acid Levels in Older Adults: Associations With Clinical Outcomes and Implications for Reference Intervals in Those Aged 70 Years and Over.Arthritis care & research · 2026Article
- The Impact of Hyperuricemia on the Progression of Atherosclerotic Cardiovascular Disease.Cureus · 2025Article
- The association between serum uric acid to high density lipoprotein ratio and cardiometabolic-related risk in adults with obesity.Endocrine · 2025Article
- A cross-sectional observational study of the association between biochemistry profiles and the risk of age-related macular degeneration.Scientific reports · 2025Observational
- Effects of antidiabetic drugs on the level of serum uric acid in patients who have type 2 diabetes.Saudi medical journal · 2025Review
- Article
- The association between insulin resistance-related markers and ASCVD with hyperuricemia: results from the 2005 to 2018 National Health and Nutrition Examination Survey.Frontiers in cardiovascular medicine · 2025Article
- Association Between Hyperuricemia, Body Composition, and Comorbidities in an Obese Pediatric Population.Journal of nutrition and metabolism · 2025Article
- Article
- Uric acid as a potential marker of cardiometabolic risk in children and adolescents with metabolic dysfunction associated steatotic liver disease.Clinical and experimental hepatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia, which has been considered as a cause of gout and nephrolithiasis has recently been suggested to be associated with hypertension, coronary heart disease, heart failure, atrial fibrillation, insulin resistance, and nonalcoholic fatty liver disease. Several clinical and experimental studies have supported uric acid (UA) as an independent risk factor for predicting disease development along with the traditional risk factors. The mechanism by which UA causes cardiometabolic disease has not been fully elucidated to date; however, it has been explained by several hypotheses such as oxidative stress, reduced nitric oxide bioavailability, inflammation, endothelial dysfunction, and so on. Although evidence of the preventive and therapeutic effects of UA lowering therapy on cardiometabolic diseases is still insufficient, it is expected to be considered as a new treatment strategy for such diseases through additional, carefully designed, large-scale clinical studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.